CellRev

Aggregation AND Agitation kill cells. For decades, we have over engineered bioprocesses to tackle common upstream inefficiencies caused by aggregation and clumping. The below graph, produced using hMSCs grown on microcarriers, shows over 60% aggregation with agitation speeds set at 30 rpm. The study goes on to state that optimal growth was seen at 60 rpm (30%+ aggregation) with 90 rpm still not capable of preventing aggregation entirely. CellRev's principal product, AggreGuard, prevents cell-to-cell bridging which initiates aggregation, at agitation speeds of 30 - 40 rpm. No shear. No aggregation. Live Cells. Lives Saved. Link to full publication in the comments. #beautifulculture #celltherapy #bioprocessing #cellculture

Chris Green and Francois Taute talking sticky cell problems at The World Vaccine Congress by Terrapinn. Does your process suffer from aggregation or clumping? Come see us on Booth 80 or drop us an email (email in the comments) #wvceu24 #beautifulculture #vaccines #therapies #bioprocessing

World Vaccine Congress Europe 2024 kicks off next week!🚀 Do you agree that low yield high cost culture should be a thing of the past? If so, come and find us at Booth 80 to discuss your optimisation needs. #cellculture #bioprocessing #beautifulculture

We are delighted to announce the appointment of Bryan Poltilove to the Board of Directors. Bryan's experience, gained at both Thermo Fisher Scientific and Johnson & Johnson, adds a new dimension to our Board. A tremendous appointment and another step in the right direction for the company. #lifescience #celltherapy #bioprocessing #team #advancedtherapies #beautifulculture

We’re here! CellRev’s CEO, Chris Green and Senior Product Manager, Harsh Bhuta are in Boston, MA for BioProcess International conference. We’re excited to share our breakthrough solutions with a global audience. Helping to accelerate the mass production of new and much-needed ATMPs, CellRev’s proprietary media additives eliminate process bottlenecks, such as aggregation, clumping, clogging and cell detachment, to increase cell viability and enable cost-effective and scalable cell culture. To learn more, connect with us at #BPI2024 or drop us a line here: https://lnkd.in/e4Af93dJ #Biotech #BiotechWeekBoston #BPIConf #Bioprocessing #LifeSciences #CellCulture #CellTherapies

Our CEO, Chris Green, will be on the start-up stage at BioTools Innovator annual #BTICapstone24 conference on Thursday 26th September. Do you use 'sticky' cells? MSCs and Fibroblasts are just two examples of cells that love sticking to one another. This leads to significant cell loss and a lot of wasted processing capacity. Come and join us if you want to talk about inefficient bioprocessing and our unique approach to optimising and intensifying cell manufacturing. #startup #biotools #lifescience #cellculture #therapeutics

Here's our CEO, Chris Green, talking about CellRev's solutions for the BioTools Innovator program. Watch our pitch video & like it on YouTube to help us win the $10K prize for the #BTIBestVideo Video > https://lnkd.in/eRcCTpZq Join Chris Green at the Capstone event in Boston on 9/26: https://hubs.ly/Q02NC6ns0. #celltherapy #bioprocessing #cellculture #stickycells

CellRev specialise in controlling cell-to-cell and cell-to-surface attachment. We have utilised our expertise in this area to launch products designed to fundamentally shift process efficiency. One such product is Livit ACE, an expansion platform for adherent cells that is capable of running in continuous mode. As part of the project, CellRev worked with Britest Limited to challenge and understand critical process parameters. Whilst continuous processing is still early in it's adoption cycle, CellRev and corporate partners Getinge, fully believe that a transition to more cost effective, scalable, and translatable processes will be key to unlocking the next wave of Cell and Gene Therapies. https://lnkd.in/eZbnKBRr ____________ Livit ACE is a bioreactor system, supplied and commissioned in partnership with Getinge, that is a combination of industry leading equipment, unique process design, and propreitary media additives that when combined enable continuous cell processing. The platform is compatible with all adherent cells and standard microcarrier process development is included. We are actively seeking research and industry partnerships to further develop the platform for application. Email us to explore - enquiry@cellrev.co.uk #celltherapy #lifesciences #bioprocessing #biopharma

We're #hiring a new Bioprocessing Technician in Newcastle Upon Tyne, England. Apply today or share this post with your network.

How healthy are my cells in microcarrier culture? “Healthy” is almost a non-sensical terminology in cell culture where we want to know the viability, proliferation and overall metabolic state of cells. Finding answers to these questions depends on the laboratory, where assay choice will be determined by many factors (available instruments; scale of experiment; budget, etc.) for the best solutions for in-line, offline and at-line assessment. Multifunctional cell counters, such as the NucleoCounter (ChemoMetec) enables total cell counts and live-to-dead ratios as readouts, based on nuclei and exclusion staining. Much preferred when compared to harvesting cells from microcarriers to do counts with the Trypan Blue method. A basic fluorescence microscope setup can be combined with opensource software like ImageJ to count stained nuclei/cells on microcarrier surfaces. Regardless of the method, always ensure you have a statistical representative sample. What would the advantages and disadvantages of the above techniques be? End-point assays, like above, provide no information about the redox-status or metabolic state the cells. The tetrazolium assays (i.e. MTT, MST, WST-1) are NAD(P)H-dehydrogenase-based but remember to account for any redox-interfering components in your setup. Stressed or dying cells have leaky cell membranes, which make lactate dehydrogenase (LDH) assays ideal companion assays. Get creative – many standard (and cheap!) 2D bioassays (apoptosis, necrosis, glutathione, ATP-content, etc.) can be adapted for microcarrier work. “Old school” biochemical assay papers are little goldmines – no one had modern process analytical equipment back in those days. If budget allows, there are biosensors (i.e. Aber Instruments Ltd Futura probe) equivalents of the above bioassays for real-time readouts. What is your biggest challenge in your microcarrier assay selection? Do you know what the difference between a viability assay and a proliferation assay is? Sartorius Stedim Biotech Cytiva Corning LifeScience #Microcarriers #AdherentCells #Vaccines #Stemcells #Bioprocessing #CellTherapy